DrugPatentWatch Database Preview
Human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant - Biologic Drug Details
Summary for human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant
| Tradenames: | 1 |
| Patents: | 5 |
| Applicants: | 1 |
| BLAs: | 1 |
| Suppliers: see list | 1 |
Patent Text Search: US Patents for human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Merck Sharp & Dohme Corp. | GARDASIL | human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant | INJECTION, SUSPENSION | 125126 | 001 | 2006-06-08 | Start Trial | Chevron Phillips Chemical Company LP (The Woodlands, TX) | 2031-06-06 | search | ||
| Merck Sharp & Dohme Corp. | GARDASIL | human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant | INJECTION, SUSPENSION | 125126 | 001 | 2006-06-08 | Start Trial | SIO2 MEDICAL PRODUCTS, INC. (Auburn, AL) | 2033-03-11 | search | ||
| Merck Sharp & Dohme Corp. | GARDASIL | human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant | INJECTION, SUSPENSION | 125126 | 001 | 2006-06-08 | Start Trial | SIO2 MEDICAL PRODUCTS, INC. (Auburn, AL) | 2029-05-13 | search | ||
| Merck Sharp & Dohme Corp. | GARDASIL | human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant | INJECTION, SUSPENSION | 125126 | 001 | 2006-06-08 | Start Trial | ALDERBIO HOLDINGS LLC (Las Vegas, NV) | 2028-11-25 | search | ||
| Merck Sharp & Dohme Corp. | GARDASIL | human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant | INJECTION, SUSPENSION | 125126 | 001 | 2006-06-08 | Start Trial | Progenra, Inc. (Malvern, PA) The Children\'s Hospital of Philadelphia (Philadelphia, PA) | 2035-07-31 | search | ||
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patents for human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 2012509871 | Start Trial |
| Australia | 2009323009 | Start Trial |
| Slovenia | 2164514 | Start Trial |
| Taiwan | I498120 | Start Trial |
| Australia | 2011332810 | Start Trial |
| Israel | 202238 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 2018 00020 | Denmark | Start Trial | PRODUCT NAME: AFUCOSYLERET ANTISTOF, DER BINDER TIL ALFA-UNDERENHEDEN AF DEN HUMANE INTERLEUKIN-5-RECEPTOR, SAERLIGT BENRALIZUMAB ELLER EN TERAPEUTISK AEKVIVALENT VARIANT DERAF, SOM ER BESKYTTET AF GRUNDPATENTET; REG. NO/DATE: EU/1/17/1252 20180110 |
| C/GB94/014 | United Kingdom | Start Trial | PRODUCT NAME: RECOMBINANT HUMAN FACTOR- VIII (BHK); REGISTERED: NL 16789 19940419; NL 16790 19940419; NL 16791 19940419; UK 0010/0194 19940517; UK 0010/0195 19940517; UK 0010/0196 19940517 |
| C/GB10/044 | United Kingdom | Start Trial | PRODUCT NAME: DENOSUMAB, IMMUNOGLOBULIN G2, ANTI-(HUMAN TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 11 (HUMAN OSTEOCLAST DIFFERENTIATION FACTOR)) HUMAN MONOCLONAL AMG162 HEAVY CHAIN), DISULPHIDE WITH HUMAN MONOCLONAL AMG162 LIGHT CHAIN, DIMER.; REGISTERED: UK EU/1/10/618/001 20100526; UK EU/1/10/618/002 20100526; UK EU/1/10/618/003 20100526; UK EU/1/10/618/004 20100526 |
| C/GB10/045 | United Kingdom | Start Trial | PRODUCT NAME: DENOSUMAB, IMMUNOGLOBULIN G2, ANTI-(HUMAN TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 11 (HUMAN OSTEOCLAST DIFFERENTIATION FACTOR)) (HUMAN MONOCLONAL AMG162 HEAVY CHAIN), DISULPHIDE WITH HUMAN MONOCLONAL AMG162 LIGHT CHAIN, DIMER; REGISTERED: UK EU/1/10/618/001 20100526; UK EU/1/10/618/002 20100526; UK EU/1/10/618/003 20100526; UK EU/1/10/618/004 20100526 |
| C/GB10/043 | United Kingdom | Start Trial | PRODUCT NAME: DENOSUMAB, IMMUNOGLOBULIN G2, ANTI-(HUMAN TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 11 (HUMAN OSTEOCLAST DIFFERENTIATION FACTOR))(HUMAN MONOCLONAL AMG 162 HEAVY CHAIN), DISULPHIDE WITH HUMAN MONOCLONAL AMG 162 LIGHT CHAIN, DIMER.; REGISTERED: UK EU/1/10/618/001 20100526; UK EU/1/10/618/002 20100526; UK EU/1/10/618/003 20100526; UK EU/1/10/618/004 20100526 |
| /2001 | Austria | Start Trial | PRODUCT NAME: RECOMBINANTES HUMANES OSTEOGENES PROTEIN-1 (OP 1); REGISTRATION NO/DATE: EU/1/01/179/001 20010517 |
| >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
